181 related articles for article (PubMed ID: 35598365)
1. Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment.
Wu X; Wang J; Liang Q; Tong R; Huang J; Yang X; Xu Y; Wang W; Sun M; Shi J
Biomed Pharmacother; 2022 Jul; 151():113116. PubMed ID: 35598365
[TBL] [Abstract][Full Text] [Related]
2. Focal adhesion kinase-An emerging viable target in cancer and development of focal adhesion kinase inhibitors.
Chauhan A; Khan T
Chem Biol Drug Des; 2021 Mar; 97(3):774-794. PubMed ID: 33191630
[TBL] [Abstract][Full Text] [Related]
3. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
Shanthi E; Krishna MH; Arunesh GM; Venkateswara Reddy K; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Oct; 24(10):1077-100. PubMed ID: 25113248
[TBL] [Abstract][Full Text] [Related]
4. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
Lu Y; Sun H
J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
[TBL] [Abstract][Full Text] [Related]
5. Development of focal adhesion kinase inhibitors in cancer therapy.
Ma WW
Anticancer Agents Med Chem; 2011 Sep; 11(7):638-42. PubMed ID: 21787276
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics.
Lv P; Chen K; Zhu HL
Curr Med Chem; 2021 Oct; 28(34):6977-6989. PubMed ID: 33797359
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.
Fukami S; Tomioka D; Murakami Y; Honda T; Hatakeyama S
BMC Res Notes; 2019 Jun; 12(1):347. PubMed ID: 31215459
[TBL] [Abstract][Full Text] [Related]
9. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis.
Zhao X; Guan JL
Adv Drug Deliv Rev; 2011 Jul; 63(8):610-5. PubMed ID: 21118706
[TBL] [Abstract][Full Text] [Related]
10. Focal adhesion kinase as a cancer therapy target.
Golubovskaya VM
Anticancer Agents Med Chem; 2010 Dec; 10(10):735-41. PubMed ID: 21214510
[TBL] [Abstract][Full Text] [Related]
11. Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders.
Yang M; Xiang H; Luo G
Biochem Pharmacol; 2024 Jun; 224():116246. PubMed ID: 38685282
[TBL] [Abstract][Full Text] [Related]
12. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
Lu H; Wang L; Gao W; Meng J; Dai B; Wu S; Minna J; Roth JA; Hofstetter WL; Swisher SG; Fang B
Mol Cancer Ther; 2013 Dec; 12(12):2864-73. PubMed ID: 24130049
[TBL] [Abstract][Full Text] [Related]
13. FAK signaling in human cancer as a target for therapeutics.
Lee BY; Timpson P; Horvath LG; Daly RJ
Pharmacol Ther; 2015 Feb; 146():132-49. PubMed ID: 25316657
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo.
Ucar DA; Magis AT; He DH; Lawrence NJ; Sebti SM; Kurenova E; Zajac-Kaye M; Zhang J; Hochwald SN
Anticancer Agents Med Chem; 2013 May; 13(4):595-602. PubMed ID: 23272972
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Wendt MK; Schiemann WP
Breast Cancer Res; 2009; 11(5):R68. PubMed ID: 19740433
[TBL] [Abstract][Full Text] [Related]
16. A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma.
Ucar DA; Cox A; He DH; Ostrov DA; Kurenova E; Hochwald SN
Anticancer Agents Med Chem; 2011 Sep; 11(7):629-37. PubMed ID: 21707510
[TBL] [Abstract][Full Text] [Related]
17. Focal adhesion kinase inhibitors are potent anti-angiogenic agents.
Cabrita MA; Jones LM; Quizi JL; Sabourin LA; McKay BC; Addison CL
Mol Oncol; 2011 Dec; 5(6):517-26. PubMed ID: 22075057
[TBL] [Abstract][Full Text] [Related]
18. Molecular Pathways: Endothelial Cell FAK-A Target for Cancer Treatment.
Roy-Luzarraga M; Hodivala-Dilke K
Clin Cancer Res; 2016 Aug; 22(15):3718-24. PubMed ID: 27262114
[TBL] [Abstract][Full Text] [Related]
19. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.
Liu W; Bloom DA; Cance WG; Kurenova EV; Golubovskaya VM; Hochwald SN
Carcinogenesis; 2008 Jun; 29(6):1096-107. PubMed ID: 18263593
[TBL] [Abstract][Full Text] [Related]
20. FAK inhibitors in Cancer, a patent review.
Lv PC; Jiang AQ; Zhang WM; Zhu HL
Expert Opin Ther Pat; 2018 Feb; 28(2):139-145. PubMed ID: 29210300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
